News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Merck KGaA Cancer Drug Erbitux Seen Limited Threat To Roche Holding AG and Genentech, Inc. Avastin
June 2, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, June 2 (Reuters) - Roche Holding AG shares jumped while Merck KGaA fell on Monday as investors decided rival drug Erbitux posed no immediate threat to Roche and Genentech Inc's cancer blockbuster Avastin.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Genentech, Inc.
MORE ON THIS TOPIC
GLP-1
Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial
October 15, 2025
·
2 min read
·
Annalee Armstrong
Podcast
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
October 15, 2025
·
1 min read
·
Heather McKenzie
Gene therapy
Regeneron Readies FDA Run for Hearing Loss Gene Therapy That Could ‘Transform Patients’ Lives’
October 13, 2025
·
2 min read
·
Tristan Manalac
Cancer
Moderna Claims Early Victory for Cancer Antigen in Melanoma
October 13, 2025
·
2 min read
·
Tristan Manalac
